1. Home
  2. BNGO vs LEXX Comparison

BNGO vs LEXX Comparison

Compare BNGO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.73

Market Cap

24.3M

Sector

Industrials

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$1.11

Market Cap

22.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
LEXX
Founded
2003
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
22.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BNGO
LEXX
Price
$1.73
$1.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$6.33
$4.00
AVG Volume (30 Days)
303.0K
151.0K
Earning Date
11-13-2025
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,720,000.00
$705,923.00
Revenue This Year
N/A
$13.35
Revenue Next Year
$24.54
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$1.45
$0.77
52 Week High
$22.80
$2.85

Technical Indicators

Market Signals
Indicator
BNGO
LEXX
Relative Strength Index (RSI) 49.79 55.92
Support Level $1.59 $1.00
Resistance Level $1.88 $1.15
Average True Range (ATR) 0.14 0.08
MACD 0.04 -0.00
Stochastic Oscillator 65.12 64.00

Price Performance

Historical Comparison
BNGO
LEXX

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: